Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
RR 0.63 [0.41, 0.96]
Studies not reported
Very low

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
OR 5.04 [2.15, 11.82]
Studies not reported
Very low

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
OR 1.24 [0.66, 2.35]
Studies not reported
Very low